Please try another search
Dis-Chem Pharmacies Limited reported earnings results for the half year ended August 31, 2023. For the half year, the company reported sales was ZAR 17,856 million compared to ZAR 16,328.08 million a year ago. Net income was ZAR 500.93 million compared to ZAR 602.54 million a year ago. Basic earnings per share from continuing operations was ZAR 0.583 compared to ZAR 0.701 a year ago. Diluted earnings per share from continuing operations was ZAR 0.583 compared to ZAR 0.7 a year ago.
Period Ending: | Aug 31, 2023 | Feb 28, 2023 | Nov 30, 2022 | Aug 31, 2022 |
---|---|---|---|---|
Total Revenue | 8167.72 | 8167.72 | 8164.04 | |
Gross Profit | 1877.63 | 1877.63 | 1916.02 | |
Operating Income | 391.3 | 391.3 | 466.29 | |
Net Income | 198.84 | 198.84 | 301.27 |
Period Ending: | Aug 31, 2023 | Feb 28, 2023 | Nov 30, 2022 | Aug 31, 2022 |
---|---|---|---|---|
Total Assets | 15515.81 | 15515.81 | 15007.81 | |
Total Liabilities | 12373.93 | 11583.33 | 11583.33 | 11198.19 |
Total Equity | 3932.48 | 3932.48 | 3809.62 |
Period Ending: | Aug 31, 2023 | Feb 28, 2023 | Nov 30, 2022 | Aug 31, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 176.73 | 176.73 | 483.25 | |
Cash From Investing Activities | -185.05 | -185.05 | -360.28 | |
Cash From Financing Activities | -287.2 | -287.2 | -47.38 | |
Net Change in Cash | -299.25 | -299.25 | 78.74 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review